Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Thiopurines in IBD: What Is Their Mechanism of Action?

Literature DB >> 20827366

Thiopurines in IBD: What Is Their Mechanism of Action?

Markus Neurath¹.

Abstract

Entities: Chemical

Year: 2010 PMID： 20827366 PMCID： PMC2933759

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

× No keyword cloud information.

5 in total

1. A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital.

Authors: B I Korelitz; D H Present
Journal: Mt Sinai J Med Date: 1996 May-Sep

2. Understanding the delayed onset of action of azathioprine in IBD: are we there yet?

Authors: Imke Atreya; Markus F Neurath
Journal: Gut Date: 2009-03 Impact factor: 23.059

3. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins.

Authors: Daniela Poppe; Imke Tiede; Gerhard Fritz; Christoph Becker; Brigitte Bartsch; Stefan Wirtz; Dennis Strand; Shinya Tanaka; Peter R Galle; Xosé R Bustelo; Markus F Neurath
Journal: J Immunol Date: 2006-01-01 Impact factor: 5.422

4. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

Authors: Imke Tiede; Gerhard Fritz; Susanne Strand; Daniela Poppe; Radovan Dvorsky; Dennis Strand; Hans Anton Lehr; Stefan Wirtz; Christoph Becker; Raja Atreya; Jonas Mudter; Kai Hildner; Brigitte Bartsch; Martin Holtmann; Richard Blumberg; Henning Walczak; Heiko Iven; Peter R Galle; Mohammad Reza Ahmadian; Markus F Neurath
Journal: J Clin Invest Date: 2003-04 Impact factor: 14.808

5. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines.

Authors: S Ben-Horin; I Goldstein; E Fudim; O Picard; Z Yerushalmi; I Barshack; I Bank; Y Goldschmid; S Bar Meir; L Mayer; Y Chowers
Journal: Gut Date: 2008-10-02 Impact factor: 23.059

5 in total

7 in total

Review 1. When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.

Authors: Suneeta Krishnareddy; Arun Swaminath
Journal: World J Gastroenterol Date: 2014-02-07 Impact factor: 5.742

2. Ras-related C3 Botulinum Toxin Substrate (Rac) and Src Family Kinases (SFK) Are Proximal and Essential for Phosphatidylinositol 3-Kinase (PI3K) Activation in Natural Killer (NK) Cell-mediated Direct Cytotoxicity against Cryptococcus neoformans.

Authors: Richard F Xiang; Danuta Stack; Shaunna M Huston; Shu Shun Li; Henry Ogbomo; Stephen K Kyei; Christopher H Mody
Journal: J Biol Chem Date: 2016-02-11 Impact factor: 5.157

Thiopurines in IBD: What Is Their Mechanism of Action?

1. A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital.

2. Understanding the delayed onset of action of azathioprine in IBD: are we there yet?

3. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins.

4. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.

5. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines.

Review 1. When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.

2. Ras-related C3 Botulinum Toxin Substrate (Rac) and Src Family Kinases (SFK) Are Proximal and Essential for Phosphatidylinositol 3-Kinase (PI3K) Activation in Natural Killer (NK) Cell-mediated Direct Cytotoxicity against Cryptococcus neoformans.

Review 3. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.

4. Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease.

Review 5. Granule-Dependent Natural Killer Cell Cytotoxicity to Fungal Pathogens.

6. Immunosuppression and Malignant Neoplasms: Risk-Benefit Assessment in Patients with Inflammatory Bowel Disease.

Review 7. Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies.